Enliven Therapeutics, Inc. (ELVN)
NMS · Healthcare · Biotechnology
$46.13
+14.30%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$2.81B
Shares Outstanding
60.9M
Exchange
NMS
Currency
USD
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -28.6M | -25.1M | -34.3M | -27.8M |
| Net Income | -25.3M | -20.1M | -29.7M | -23.6M |
| Diluted EPS | $-0.49 | $-0.32 | $-0.48 | $-0.38 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -38.8M | -83.5M | -104.6M | -119.7M |
| Net Income | -37.7M | -71.6M | -89.0M | -103.7M |
| Diluted EPS | $-0.92 | $-2.01 | $-1.89 | $nan |